NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY

Authors

  • I. Kriachok State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • I. Tytorenko State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • N. Shudrak State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • O. Aleksik State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • Ya. Stepanishyna State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • T. Kadnikova State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • Ya. Pastushenko State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • N. Shokun State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • T. Rudiyk State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • M. Bushuieva State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2023.04.474

Keywords:

T-cell lymphoma, not otherwise specified T-cell lymphoma, incidence, prognostic factor, response, survival

Abstract

Background. The peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of peripheral T-cell lymphoma (PTCL). It constitutes approximately 25% of all PTCLs and accounts for more than 15% of all lymphomas. The results of the first Ukrainian prospective study of patients with PTCL-NOS are presented in the article. The aim of the study was to analyze the morbidity of PTCL patients and the treatment performed, to evaluate overall survival and progression-free survival, and to determine the factors that predict the treatment response. Patients and Methods. An analysis was performed on the data of 31 patients diagnosed with peripheral PTCL-NOS from February 2018 to the present. T-cell lymphoid neoplasms were diagnosed according to the 2016 WHO classification. The treatment regimens were in alignment with ESMO and NCCN guidelines. More than 90% of patients were prescribed anthracycline-based regimens (CHOP; CHOEP — cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone). An initial treatment was performed with CHOP-based regimens in 38.70% (n = 12) of patients, with the addition of etoposide in 58.06% of patients (n = 18). Results. The response was assessed according to the response criteria for malignant lymphoma (Cheson, 2008, 2014). The overall response to therapy was 58.06% (n = 18), with complete responses in 29.03% of patients and partial responses in 29.03% of patients. The stabilization of the disease occurred in 3.44%, while the disease progression in 41.37% of patients. The 12-month and 24-month survival rates were 75.44% and 50.81%, respectively. The 12-month and 24-month progression-free survivals were 47.68% and 33.1%, respectively. Ki-67 overexpression (> 65%) was a negative prognostic factor. Conclusions. The results of the treatment of PTCL obtained in a Ukrainian population study are similar to those in other European studies, all of which remain unsatisfactory. Further research is required to develop a new strategy for examination and therapy to improve treatment outcomes. The emphasis should be placed on the pragmatic clinical trials comparing the efficacy of first-line treatment in PTCL patients with both favorable and unfavorable clinical factors.

References

Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell andnaturalkiller/T-celllymphomastudy: pathologyfindingsandclinicaloutcomes. JClin Oncol. 2008;26(25):4124- 4130. https://doi.org/10.1200/JCO.2008.16.4558

Zinzani PL, Broccoli A. T-cell lymphoproliferative disorders. In: Hoffbrand V, Higgs DR, Keeling DM, et al, eds. Postgraduate Hematology, 7th ed. Hoboken, NJ: Wiley Blackwell, 2016:524-536.

Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007;117(3):823-834. https://doi.org/10.1172/JCI26833

Iqbal J, Weisenburger DD, Greiner TC, et al; International Peripheral T-Cell Lymphoma Project. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-1036. https://doi.org/10.1182/blood-2009-06-227579

Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31(24):3019–3025. DOI:10.1200/JCO.2012.42.5611

Gallamini A, Stelitano C, Calvi R, et al; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479. https://doi.org/10.1182/blood-2003-09-3080

Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472-2479. https://doi.org/10.1200/JCO.2005.03.6327

Vose JM. International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines [abstract]. Blood. 2005;106(11):Abstract811. https://doi.org/10.1182/blood.V106.11.811.811

Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467-1475. https://doi.org/10.1093/annonc/mdh392.

Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211–2217. https://doi.org/10.1093/annonc/mdu443.

Pinter-Brown L, Foss FM, Carson KR, et al. Patient characteristics and initial treatment patterns in the United States for the most common subtypes of peripheral T-cell lymphoma (PTCL) [abstract]. Blood. 2014;124(21):Abstract 4434.

Abouyabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline- based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011; 2011:623924. https://doi.org/10.5402/2011/623924.

Briski R, Feldman AL, Bailey NG, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214. https://doi.org/10.1038/bcj.2014.34

Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High- Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418-3425. https://doi.org/10.1182/blood-2010-02-270785

Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533-1538. https://doi.org/10.1038/sj.leu.2404306

d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093-3099. https://doi.org/10.1200/JCO.2011.40.2719

Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81-e82. https://doi.org/10.3324/haematol.2013.084913

Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983-2986. https://doi.org/10.1182/blood-2014-07-584953

Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095-3100. doi.org/10.1182/blood-2013-12-542142

Lamarque M, Bossard C, Contejean A, et al. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica. 2016;101(3):e103-e106. https://doi.org/10.3324/haematol.2015.135400

Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. https://doi.org/10.1182/blood-2016-01-643569. https://doi.org/10.1182/blood-2016-01-643569

Cheson B. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am. 2008;46(2):213-223, vii. https://doi.org/10.1016/j.rcl.2008.03.003. DOI:10.1016/j.rcl.2008.03.003

Bellei M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: A report from the prospective International T-Cell Project. Haematologica. 2019;104:e178. https://doi.org/10.3324/haematol.2017.186577

Downloads

Published

03.02.2024

How to Cite

Kriachok, I., Tytorenko, I., Shudrak, N., Aleksik, O., Stepanishyna, Y., Kadnikova, T., … Bushuieva, M. (2024). NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY. Experimental Oncology, 45(4), 474–482. https://doi.org/10.15407/exp-oncology.2023.04.474

Issue

Section

Original contributions

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)